6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. J of Skin 2023, 7 (6), s232. https://doi.org/10.25251/skin.7.supp.232.